---
title: "Buy Rating Reaffirmed on BioAge: Sell-Off Seen as Overdone Amid Validated NLRP3 Platform and Triple-Digit Upside Potential"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294548354.md"
description: "Citi analyst Samantha Semenkow reaffirmed a Buy rating on BioAge Labs with a $52 price target, viewing the recent sell-off following Novo's ZEUS trial failure as overdone. The analyst cites validated NLRP3 platform potential, upcoming Phase 2 data for BGE-102, and strong cash reserves as drivers for triple-digit upside. Jefferies also maintained a Buy rating with a $21 target."
datetime: "2026-07-31T18:36:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294548354.md)
  - [en](https://longbridge.com/en/news/294548354.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294548354.md)
generator: "portal-rs"
---

# Buy Rating Reaffirmed on BioAge: Sell-Off Seen as Overdone Amid Validated NLRP3 Platform and Triple-Digit Upside Potential

Analyst Samantha Semenkow of Citi maintained a Buy rating on BioAge Labs, Inc., with a price target of $52.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Samantha Semenkow has given his Buy rating due to a combination of factors tied to both valuation and pipeline strength. Despite the recent sell-off driven by Novo’s ZEUS trial failure, he views the market reaction as excessive, with BioAge’s enterprise value now near zero relative to the potential of its NLRP3 inhibitor platform and broader inflammatory disease strategy.

Moreover, he highlights that upstream IL-1β and NLRP3 inhibition remain scientifically validated targets, supporting continued development across cardiovascular and non-cardiovascular indications. With upcoming Phase 2 data for BGE-102, a planned ophthalmology study, and sufficient cash to fund another proof-of-concept trial, he sees a compelling risk/reward profile that justifies a Buy rating and a triple-digit expected return potential.

Semenkow covers the Healthcare sector, focusing on stocks such as Nektar Therapeutics, Larimar Therapeutics, and Wave Life Sciences. According to TipRanks, Semenkow has an average return of 4.7% and a 48.85% success rate on recommended stocks. 

In another report released today, Jefferies also maintained a Buy rating on the stock with a $21.00 price target.

### Related Stocks

- [BIOA.US](https://longbridge.com/en/quote/BIOA.US.md)
- [C.US](https://longbridge.com/en/quote/C.US.md)
- [NVO.US](https://longbridge.com/en/quote/NVO.US.md)
- [NKTR.US](https://longbridge.com/en/quote/NKTR.US.md)
- [LRMR.US](https://longbridge.com/en/quote/LRMR.US.md)
- [WVE.US](https://longbridge.com/en/quote/WVE.US.md)
- [JEF.US](https://longbridge.com/en/quote/JEF.US.md)
- [C-R.US](https://longbridge.com/en/quote/C-R.US.md)

## Related News & Research

- [BioAge Therapeutics: Buy Rating Maintained Despite Cut in Price Target to $21 on Refined ASCVD and Ocular Program Assumptions](https://longbridge.com/en/news/294547996.md)
- [Roth MKM Reaffirms Their Buy Rating on BioAge Labs, Inc. (BIOA)](https://longbridge.com/en/news/294546673.md)
- [Alliance Global Partners Reaffirms Their Buy Rating on Pelthos Therapeutics (PTHS)](https://longbridge.com/en/news/296781912.md)
- [Freeport-McMoRan (FCX): New Buy Recommendation for This Basic Materials Giant](https://longbridge.com/en/news/296794439.md)
- [Maxim Group Reaffirms Their Buy Rating on Our Bond Inc (OBAI)](https://longbridge.com/en/news/296798454.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**